

File reference	W17FOI027
Key words	Intra-vitreous Vials
Date of release	02/05/2017
Attachments	No

Freedom of Information Act Disclosure log - Reply Extract

You asked

Within your trust, how many intra-vitreous vials/implants have been used in the latest 4 months, if possible between September and December 2016. Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use

	Lucentis (ranibizumab) Injections	Avastin (bevacizumab) Injections	Eylea (aflibercept) Injections	Iluvien (Fluocinolone) Implants	Ozurdex (Dexamethasone) Implants
Total Vials / Implants	1505	14	819	Five or fewer	119
Vials for wet AMD	1035 injections / 511 eyes / 450 patients	0	687 injections / 346 eyes / 297 patients	0	0
Vials for other conditions [DMO, RVO, CNV, Uveitis]	470 injections / 255 eyes / 219 patients	14 / 11 eyes / 10 patients	132 injections / 63 eyes / 55 patients	Five or fewer injections / five or fewer eyes / five or fewer patients	119 injections / 118 eyes / 114 patients

Does your trust record the time taken from referral of a patient for treatment to the time for an injection or implant to be complete?

Yes

If so, what is the average waiting time for treatment with an injection or implant?

The average waiting time for these 10 patients was 3.8 weeks.

Legal notes

Plymouth Hospitals NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles. This is in accordance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i), the personal information exemption as described in the Freedom of Information Act. A detailed rationale is provided in the attached document L3.

Attachments included: L3